Harshad R. Kulkarni

Harshad R. Kulkarni

Robert Koch Allee 9
Bad Berka, TH 99437, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 90 publications

Building Sustainable Theranostics Programs: Operational Models, Access, and Equity.

Building Sustainable Theranostics Programs: Operational Models, Access, and Equity.

Journal: PET clinics

Published: May 05, 2026

Theranostics: When Targeted Imaging Guides Targeted Therapy.

Theranostics: When Targeted Imaging Guides Targeted Therapy.

Journal: PET clinics

Published: May 01, 2026

Artificial Intelligence Across the PSMA Theranostic Continuum in Prostate Cancer.

Artificial Intelligence Across the PSMA Theranostic Continuum in Prostate Cancer.

Journal: PET clinics

Published: April 12, 2026

Artificial Intelligence Across the PSMA Theranostic Continuum in Prostate Cancer.

Artificial Intelligence Across the PSMA Theranostic Continuum in Prostate Cancer.

Journal: PET clinics

Published: April 12, 2026

From Feasibility to Durability: The Next Phase of Theranostics.

From Feasibility to Durability: The Next Phase of Theranostics.

Journal: PET clinics

Published: April 10, 2026

Prostate-Specific Membrane Antigen Positron Emission Tomography-Detected Intrahepatic Cholangiocarcinoma in a Patient With Metastatic Castration-Resistant Prostate Cancer: Dual Cancer Management With Pluvicto and Intensity-Modulated Radiation Therapy.

Prostate-Specific Membrane Antigen Positron Emission Tomography-Detected Intrahepatic Cholangiocarcinoma in a Patient With Metastatic Castration-Resistant Prostate Cancer: Dual Cancer Management With Pluvicto and Intensity-Modulated Radiation Therapy.

Journal: Cureus

Published: August 15, 2025

Evaluating the Efficacy and Safety of Pluvicto in Chemotherapy-Ineligible Nonagenarians: A Descriptive Case Series.

Evaluating the Efficacy and Safety of Pluvicto in Chemotherapy-Ineligible Nonagenarians: A Descriptive Case Series.

Journal: Cureus

Published: February 16, 2025

Long-term Efficacy, Survival, and Toxicity of Peptide Receptor Radionuclide Therapy in Patients With Refractory Meningioma.

Long-term Efficacy, Survival, and Toxicity of Peptide Receptor Radionuclide Therapy in Patients With Refractory Meningioma.

Journal: Clinical nuclear medicine

Published: December 03, 2024

The PANEN nomogram: clinical decision support for patients with metastatic pancreatic neuroendocrine neoplasm referred for peptide receptor radionuclide therapy.

The PANEN nomogram: clinical decision support for patients with metastatic pancreatic neuroendocrine neoplasm referred for peptide receptor radionuclide therapy.

Journal: Frontiers in endocrinology

Published: October 22, 2024

Dosimetry of [177Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial.

Dosimetry of [177Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: September 30, 2024

Expert consensus on workflow of PET/CT with long axial field-of-view.

Expert consensus on workflow of PET/CT with long axial field-of-view.

Journal: European journal of nuclear medicine and molecular imaging

Published: July 15, 2024

Immune Response to Molecular Radiotherapy with 177Lu-DOTATOC: Predictive Value of Blood Cell Counts for Therapy Outcome.

Immune Response to Molecular Radiotherapy with 177Lu-DOTATOC: Predictive Value of Blood Cell Counts for Therapy Outcome.

Journal: Cancer biotherapy & radiopharmaceuticals

Published: June 21, 2024

Showing 1-12 of 90

Last Updated: 09/26/2026